Further investigation is required to delineate the minimum and maximum thresholds of MBNL1 overexpression in vitro and in vivo in order to observe MBNL1-mediated correction of DM1 pathology without reaching toxicity. The gene discussed is MBNL1; the disease is myotonic dystrophy type 1.